ALS Therapy Development Institute

ALS Therapy Development Institute, Neurimmune partner for ALS

Friday, December 6, 2013 12:51 PM

The ALS Therapy Development Institute (ALS TDI) and its wholly-owned subsidiary, Anelixis Therapeutics, a translational medicine and drug development company, have partnered with Swiss biotech company Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease.

More... »


ALS TDI, Gladstone Institutes to discover potential ALS treatments

Wednesday, December 5, 2012 09:44 AM

The ALS Therapy Development Institute (ALS TDI), aimed at developing effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS), and the Gladstone Institutes, a nonprofit biomedical-research organization, have formed a research collaboration to speed the discovery of potential treatments for ALS through the preclinical drug development process.

More... »


ALS TDI, Regenesance partner on Lou Gehrig’s disease

Monday, May 7, 2012 12:35 PM

Cambridge, Mass.-based ALS Therapy Development Institute (ALS TDI), one of the largest ALS drug development centers, has entered into a partnership with Netherlands-based biotech Regenesance to investigate a potential treatment for Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.

More... »

ALS Therapy to launch phase II trial of TDI 132

Wednesday, February 15, 2012 04:03 PM

The ALS Therapy Development Institute, a nonprofit biotech, will be launching a phase II clinical trial on TDI 132 (fingolimod)—currently used as treatment for multiple sclerosis—as a potential treatment for ALS (Lou Gehrig's disease). 

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs